09.04.2019

• The Institut Pasteur will provide a selection of strains for the DEINOVE platform to evaluate their potential antibiotic and antifungal activities.
• This agreement fits into the AGIR program, which aims at studying a wide range of bacterial strains to optimize opportunities for discovering novel antibiotic structures.

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, has announced that it will benefit from the Institut Pasteur's provision of biological resources for the research of new antimicrobial agents from original strains.The Institut Pasteur, one of the most renowned worldwide players in the area of infectious disease research, will entrust a targeted selection of strains from their bacterial collection to DEINOVE.As part of their AGIR program (Antibiotics against Resistant Infectious Germs), DEINOVE will assess the strains' antimicrobial properties on their technology platform.Muriel GUGGER, Head of the Institut Pasteur's laboratory collection of Cyanobacteria whose work is supported by Institut Carnot Pasteur Microbes & Santé, explained, "The selected bacteria produce a wide range of natural substances and therefore constitute a goldmine for research.” As Isabelle BUCKLE, Executive vice president for Research Applications and Industrial Partnerships at Institut Pasteur, detailed, "Antimicrobial resistance is among the Institut Pasteur’s top three scientific priorities, and the development of industrial partnerships with French SMEs is at the heart of our economic development strategy in the coming years.In this context, the DEINOVE platform will allow us to quickly assess the potential of our strains."Georges GAUDRIAULT, Scientific Director at DEINOVE, pointed out, "The Institut Pasteur is a major player in the area of infectious disease research. We are delighted to be able to benefit from their expertise and proud that the quality of our scientific approach has convinced them to work with us. We firmly believe that this agreement will be a real booster for the AGIR program."Source: http://www.deinove.com/en/news/all-press-releases/novel-antibiotics-deinove-signs-agreement-institut-pasteur-explore-potential-new-targeted-strains